瀰漫大B细胞淋巴瘤治疗市场－全球产业规模、份额、趋势、机会和预测（按药物类别、疗法、最终用户、地区和竞争细分，2020-2030年预测）

2024 年全球瀰漫大 B 细胞淋巴瘤治疗市场价值为 40.2 亿美元，预计在预测期内将达到 63.6 亿美元，到 2030 年的复合年增长率为 7.91%。全球瀰漫大 B 细胞淋巴瘤 (DLBCL) 治疗市场正在经历显着增长，原因是发病率上升、标靶治疗的进步以及对早期诊断的认识不断提高。 DLBCL 是非何杰金氏淋巴瘤最常见的亚型，其病例数激增，推动了对有效治疗方案的需求。市场受益于新型疗法的不断扩大批准，包括 CAR-T 细胞治疗、双特异性抗体和单株抗体，这些疗法正在提高存活率并为復发或难治性疾病患者带来新的希望。製药公司和研究机构正在积极投资药物开发，从而形成了强大的创新疗法管道。向个人化医疗和生物标记驱动的治疗方法的转变正在进一步彻底改变市场，使得客製化治疗能够增强治疗效果并减少副作用。

主要市场驱动因素

瀰漫大B细胞淋巴瘤（DLBCL）发生率上升

主要市场挑战

创新疗法成本高

主要市场趋势

免疫疗法革命

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：全球瀰漫大B细胞淋巴瘤治疗市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依药物类别（顺铂、卡铂、5-氟尿嘧啶、多西他赛、紫杉醇、甲胺蝶呤、其他药物）
  • 按疗法（标靶治疗、免疫疗法、化疗、其他疗法）
  • 按最终使用者（医院和诊所、门诊护理中心、其他）
  • 按地区
  • 按公司分类（2024）
• 市场地图
  • 按药物类别
  • 透过治疗
  • 按最终用户
  • 按地区

第五章：亚太地区瀰漫大B细胞淋巴瘤治疗市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按药物类别
  • 透过治疗
  • 按最终用户
  • 按国家
• 亚太地区：国家分析
  • 中国
  • 印度
  • 澳洲
  • 日本
  • 韩国

第六章：欧洲瀰漫大B细胞淋巴瘤治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 西班牙
  • 义大利
  • 英国

第 7 章：北美瀰漫性大 B 细胞淋巴瘤治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 墨西哥
  • 加拿大

第 8 章：南美洲瀰漫大 B 细胞淋巴瘤治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第九章：中东和非洲瀰漫大B细胞淋巴瘤治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋

第十章：市场动态

• 驱动程式
• 挑战

第 11 章：市场趋势与发展

• 最新动态
• 产品发布
• 合併与收购

第 12 章：全球瀰漫大 B 细胞淋巴瘤治疗市场：SWOT 分析

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 14 章：竞争格局

• Gilead Sciences Inc
• Novartis AG
• Pfizer Inc.
• Merck & Co. Inc.
• GlaxoSmithKline plc
• F. Hoffmann-La Roche Ltd.
• CTI BioPharma Corp.
• Celltrion Healthcare Co. Ltd.
• Bristol Myers Squibb Company
• AbbVie Inc

第 15 章：策略建议

第16章调查会社について・免责事项

Global Diffuse Large B-cell Lymphoma Therapeutics Market was valued at USD 4.02 Billion in 2024 and is expected to reach USD 6.36 Billion in the forecast period with a CAGR of 7.91% through 2030. The Global Diffuse Large B-cell Lymphoma (DLBCL) Therapeutics Market is experiencing significant growth due to rising incidence rates, advancements in targeted therapies, and increasing awareness about early diagnosis. DLBCL, the most common subtype of non-Hodgkin's lymphoma, has seen a surge in cases, driving demand for effective treatment options. The market is benefiting from the expanding approval of novel therapies, including CAR-T cell treatments, bispecific antibodies, and monoclonal antibodies, which are improving survival rates and offering new hope for patients with relapsed or refractory disease. Pharmaceutical companies and research institutions are actively investing in drug development, leading to a robust pipeline of innovative therapies. The shift toward personalized medicine and biomarker-driven treatment approaches is further revolutionizing the market, enabling tailored therapies that enhance treatment efficacy and reduce adverse effects.

Key Market Drivers

Rising Incidence of Diffuse Large B-cell Lymphoma (DLBCL)

The rising incidence of Diffuse Large B-cell Lymphoma (DLBCL) is a significant driving force behind the growth of the global DLBCL therapeutics market. DLBCL is the most common subtype of non-Hodgkin lymphoma (NHL), accounting for approximately 25% to 30% of all NHL cases worldwide. In the United States, the age-standardized incidence rate for DLBCL is 7.2 per 100,000 individuals, with higher rates observed among non-Hispanic whites (9.2 per 100,000). In the United Kingdom, about 5,000 people are diagnosed with DLBCL annually, representing more than 40% of adult NHL cases. This increasing prevalence is a cause for concern and a catalyst for innovative treatment approaches.

Several factors contribute to the escalating incidence of DLBCL. The aging global population is a significant factor, as DLBCL predominantly affects older adults. Most individuals diagnosed with DLBCL are 65 years or older. As life expectancy increases, the number of older individuals at risk for DLBCL rises, thereby expanding the patient population in need of treatment.

Key Market Challenges

High Cost of Innovative Therapies

The high cost of innovative therapies stands as a significant barrier hindering the global Diffuse Large B-cell Lymphoma (DLBCL) therapeutics market. DLBCL, as one of the most common subtypes of non-Hodgkin lymphoma, necessitates cutting-edge treatments to improve patient outcomes. However, the exorbitant prices associated with these therapies create formidable challenges for both patients and healthcare systems.

In recent years, the development of novel treatments, such as Chimeric Antigen Receptor T-cell therapy (CAR-T therapy) and targeted drugs, has provided new hope for DLBCL patients. CAR-T therapy, for instance, involves genetically modifying a patient's T-cells to attack cancer cells specifically. While these therapies offer remarkable results, they often come with a staggering price tag. CAR-T therapies can cost hundreds of thousands of dollars, putting them out of reach for many patients.

Key Market Trends

Immunotherapy Revolution

The immunotherapy revolution is playing a pivotal role in boosting the global Diffuse Large B-cell Lymphoma (DLBCL) therapeutics market. DLBCL, being a prevalent and aggressive subtype of non-Hodgkin lymphoma, has long posed significant challenges for treatment. However, recent breakthroughs in immunotherapy have transformed the landscape of DLBCL therapeutics.

Immune checkpoint inhibitors, such as nivolumab and pembrolizumab, are among the key drivers of this revolution. These drugs work by blocking specific proteins that inhibit the immune system's response to cancer cells. In DLBCL, they have shown promising results by reinvigorating the body's immune defenses against cancer. Patients who have exhausted conventional treatment options, especially those with relapsed or refractory DLBCL, have witnessed remarkable responses to these immunotherapies.

Another groundbreaking immunotherapy approach in DLBCL is Chimeric Antigen Receptor T-cell therapy (CAR-T therapy). CAR-T therapies, like axicabtagene ciloleucel and tisagenlecleucel, involve genetically modifying a patient's own T-cells to express chimeric antigen receptors that target specific proteins on the surface of DLBCL cells. This precise targeting has led to high response rates and prolonged remissions in some patients, even those with refractory disease.

Key Market Players

• Gilead Sciences Inc
• Novartis AG
• Pfizer Inc.
• Merck & Co. Inc.
• GlaxoSmithKline plc
• F. Hoffmann-La Roche Ltd.
• CTI BioPharma Corp.
• Celltrion Healthcare Co. Ltd.
• Bristol Myers Squibb Company
• AbbVie Inc

Report Scope:

In this report, the Global Diffuse Large B-cell Lymphoma Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Diffuse Large B-cell Lymphoma Therapeutics Market, By Drug Class:

• Cisplatin
• Carboplatin
• 5-fluorouracil
• Docetaxel
• Paclitaxel
• Methotrexate
• Other Drugs

Global Diffuse Large B-cell Lymphoma Therapeutics Market, By Therapy:

• Targeted Therapy
• Immunotherapy
• Chemotherapy
• Other Therapies

Global Diffuse Large B-cell Lymphoma Therapeutics Market, By End-User:

• Hospitals &Clinics
• Ambulatory care Centers
• Others

Global Diffuse Large B-cell Lymphoma Therapeutics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Diffuse Large B-cell Lymphoma Therapeutics Market.

Available Customizations:

Global Diffuse Large B-cell Lymphoma Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Diffuse Large B-cell Lymphoma Therapeutics Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Drug Class (Cisplatin, Carboplatin, 5-fluorouracil, Docetaxel, Paclitaxel, Methotrexate, Other Drugs)
  • 4.2.2. By Therapy (Targeted Therapy, Immunotherapy, Chemotherapy, Other Therapies)
  • 4.2.3. By End-User (Hospitals & Clinics, Ambulatory care Centers, Others)
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Drug Class
  • 4.3.2. By Therapy
  • 4.3.3. By End-User
  • 4.3.4. By Region

5. Asia Pacific Diffuse Large B-cell Lymphoma Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class
  • 5.2.2. By Therapy
  • 5.2.3. By End-User
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Drug Class
      • 5.3.1.2.2. By Therapy
      • 5.3.1.2.3. By End-User
  • 5.3.2. India Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Drug Class
      • 5.3.2.2.2. By Therapy
      • 5.3.2.2.3. By End-User
  • 5.3.3. Australia Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Drug Class
      • 5.3.3.2.2. By Therapy
      • 5.3.3.2.3. By End-User
  • 5.3.4. Japan Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Drug Class
      • 5.3.4.2.2. By Therapy
      • 5.3.4.2.3. By End-User
  • 5.3.5. South Korea Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Drug Class
      • 5.3.5.2.2. By Therapy
      • 5.3.5.2.3. By End-User

6. Europe Diffuse Large B-cell Lymphoma Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Therapy
  • 6.2.3. By End-User
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Therapy
      • 6.3.1.2.3. By End-User
  • 6.3.2. Germany Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Therapy
      • 6.3.2.2.3. By End-User
  • 6.3.3. Spain Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Therapy
      • 6.3.3.2.3. By End-User
  • 6.3.4. Italy Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Drug Class
      • 6.3.4.2.2. By Therapy
      • 6.3.4.2.3. By End-User
  • 6.3.5. United Kingdom Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Drug Class
      • 6.3.5.2.2. By Therapy
      • 6.3.5.2.3. By End-User

7. North America Diffuse Large B-cell Lymphoma Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Therapy
  • 7.2.3. By End-User
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Therapy
      • 7.3.1.2.3. By End-User
  • 7.3.2. Mexico Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Therapy
      • 7.3.2.2.3. By End-User
  • 7.3.3. Canada Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Therapy
      • 7.3.3.2.3. By End-User

8. South America Diffuse Large B-cell Lymphoma Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Therapy
  • 8.2.3. By End-User
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Therapy
      • 8.3.1.2.3. By End-User
  • 8.3.2. Argentina Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Therapy
      • 8.3.2.2.3. By End-User
  • 8.3.3. Colombia Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Therapy
      • 8.3.3.2.3. By End-User

9. Middle East and Africa Diffuse Large B-cell Lymphoma Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Therapy
  • 9.2.3. By End-User
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Therapy
      • 9.3.1.2.3. By End-User
  • 9.3.2. Saudi Arabia Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Therapy
      • 9.3.2.2.3. By End-User
  • 9.3.3. UAE Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Therapy
      • 9.3.3.2.3. By End-User

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Diffuse Large B-cell Lymphoma Therapeutics Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Gilead Sciences Inc
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Novartis AG
• 14.3. Pfizer Inc.
• 14.4. Merck & Co. Inc.
• 14.5. GlaxoSmithKline plc
• 14.6. F. Hoffmann-La Roche Ltd.
• 14.7. CTI BioPharma Corp.
• 14.8. Celltrion Healthcare Co. Ltd.
• 14.9. Bristol Myers Squibb Company
• 14.10. AbbVie Inc

15. Strategic Recommendations

16. About Us & Disclaimer